HIV Prevention and Alcohol (R01 Clinical Trials Optional)
ID: 348094Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/348094

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAS-23-173.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "HIV Prevention and Alcohol," aimed at enhancing HIV/AIDS prevention strategies among populations affected by alcohol use. The initiative seeks to integrate effective interventions and develop novel strategies tailored to diverse subpopulations at increased risk for HIV acquisition, focusing on key research areas such as PrEP utilization, Treatment as Prevention, and syndemic approaches. This grant reflects a commitment to addressing health disparities and improving outcomes for populations impacted by both alcohol misuse and HIV, with NIH planning to fund 2-4 awards totaling approximately $2 million for fiscal year 2024. Interested applicants must adhere to NIH guidelines and submit their proposals by May 7, 2026; for further inquiries, they can contact NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAS-23-173-Full-Announcement.html
    PAS-23-173.html
    The National Institutes of Health (NIH) offers a funding opportunity titled "HIV Prevention and Alcohol" aimed at expanding HIV/AIDS prevention strategies among alcohol-affected populations. This initiative seeks to integrate effective interventions and implement novel strategies tailored to diverse subpopulations with varying patterns of alcohol use and increased risk for HIV acquisition. Key research areas of interest include PrEP utilization, Treatment as Prevention, integration of preventive strategies, syndemic approaches, and implementation science. The program encourages applications that address the epidemiological surge of HIV incidents, particularly in high-risk groups such as men who have sex with men, women with high-risk partners, and individuals in geographic HIV/AIDS "hot spots". The NIH plans to fund 2-4 awards totaling approximately $2 million for fiscal year 2024, with an application period extending until May 2026. Organizations eligible to apply include higher education institutions, non-profits, and government entities, with an emphasis on increasing participation from underrepresented groups. Applications must adhere strictly to NIH guidelines and include comprehensive research designs and data management plans. This grant reflects a commitment to address health disparities and improve health outcomes for populations affected by both alcohol misuse and HIV.
    Similar Opportunities
    HIV Prevention and Alcohol (R34 Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "HIV Prevention and Alcohol (R34 Clinical Trials Optional)" aimed at expanding the HIV/AIDS prevention toolkit among populations impacted by alcohol use. This grant seeks to support research that integrates effective prevention and treatment interventions while addressing the behavioral and biological risks associated with alcohol consumption, particularly among high-risk groups. The initiative is crucial for informing the design of future clinical trials focused on HIV prevention, with an anticipated funding amount of approximately $1.5 million for 2-4 awards. Interested applicants, including higher education institutions and community organizations, must submit their proposals by September 7, 2025, and can find additional information at NIH Grants or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)" aimed at supporting innovative research that addresses the intersection of HIV and substance use. This initiative invites applications from individual researchers and research teams to develop projects that can lead to new prevention, treatment, and care strategies for individuals affected by both conditions, with a requirement for a detailed research plan and preliminary data. A total budget of $3.0 million is available for funding one to two awards, with individual project budgets capped at $1.5 million per fiscal year, and applications are due by February 12, 2027. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and are encouraged to consult with NIDA program staff early in the application process.
    Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R34 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services," aimed at supporting innovative research to enhance the integration of HIV, addiction, and primary care services. This initiative invites applications for R34 Planning Grants to develop and test models that improve healthcare delivery for individuals at risk for or living with HIV, Hepatitis B and C, and substance use disorders, with a focus on strategies such as integrating substance misuse prevention within HIV care settings. The total funding available for this project is $2 million, with awards potentially lasting up to three years, and applications are due by March 20, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)" aimed at supporting innovative research at the intersection of HIV and substance use. This initiative seeks proposals that address critical gaps in understanding and improving health outcomes for individuals living with HIV who also face substance use disorders, requiring detailed research plans and preliminary data from both individual researchers and research teams. NIH plans to allocate approximately $3 million annually for three to five awards over three years, with applications due by January 11, 2025, and a strong emphasis on enhancing diverse perspectives through an inclusion plan. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-024.html.
    Development and Testing of Novel Interventions to improve HIV Prevention, Treatment, and Program Implementation for People Who Use Drugs (R34 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity (PA-21-205) aimed at the development and testing of innovative interventions to enhance HIV prevention, treatment, and program implementation for individuals who use drugs. This R34 grant focuses on formative research and pilot studies that assess the feasibility, safety, and acceptability of various interventions, including behavioral, social, and structural approaches, particularly integrating substance use considerations into HIV care. The initiative is crucial in addressing the ongoing challenges of the HIV epidemic among populations significantly impacted by substance use, with projects expected to enhance HIV testing, preventive services, and treatment adherence. Interested applicants can apply for grants with a ceiling of $225,000, and the application deadline is January 7, 2025. For further information, contact the NIH OER Webmaster at grantsinfo@nih.gov or visit the funding announcement at http://grants.nih.gov/grants/guide/pa-files/PA-21-205.html.
    Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R34 Clinical Trial optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services," aimed at supporting innovative research in integrated care models for HIV/AIDS and substance use disorders. The initiative seeks to improve health outcomes and enhance care coordination for individuals at heightened risk by addressing service delivery gaps through collaborative and evidence-based practices. This grant, with a funding ceiling of $450,000 over three years, is open to a diverse range of eligible applicants, including higher education institutions and community-based organizations, with applications due by March 19, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-020.html.
    Exploratory Studies to Investigate Mechanisms of HIV infection, Replication, Latency, and/or Pathogenesis in the Context of Substance Use Disorders (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Exploratory Studies to Investigate Mechanisms of HIV infection, Replication, Latency, and/or Pathogenesis in the Context of Substance Use Disorders" through the R01 Research Project Grant. This initiative aims to support innovative and high-risk studies that explore the molecular mechanisms linking HIV and substance use disorders (SUDs), with a focus on advancing understanding of HIV dynamics within the Central Nervous System (CNS). The total estimated program funding is $2 million for fiscal year 2026, with the potential to support up to three awards, and applications must include clear milestones and human or primate studies. Interested applicants should note that the deadline for submitting letters of intent and applications is July 14, 2025, and no clinical trials are permitted under this grant. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R01 Clinical Trial required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services," aimed at testing innovative care models that integrate HIV, addiction, and primary care services. This initiative seeks to address gaps in comprehensive health service delivery for individuals at heightened risk for HIV or living with HIV and substance use disorders, emphasizing the need for replicable and sustainable interventions. The program is critical for enhancing service delivery to vulnerable populations and aligns with national public health goals to combat the HIV epidemic in the United States. Interested applicants can apply for a share of the $2 million funding by March 20, 2025, and should direct inquiries to grantsinfo@nih.gov or visit the full announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-019.html for more details.
    Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R01 Clinical Trial required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services," aimed at supporting R01 Clinical Trials. This initiative seeks to develop and evaluate innovative care models that effectively integrate services for HIV/AIDS, substance use disorders (SUD), and optional hepatitis, with the goal of enhancing healthcare delivery and improving health outcomes for affected individuals. The program aligns with the "Ending the HIV Epidemic: A Plan for America" initiative and emphasizes the importance of coordinated care in settings such as Federally Qualified Health Centers. Eligible applicants include various institutions and organizations, with an expected award budget of up to $2 million for fiscal year 2026 and a project duration of up to five years. Interested parties can find more information and submit inquiries via email to grantsinfo@nih.gov, with applications due by March 19, 2025.
    Innovations to Optimize HIV Prevention and Care Continuum Outcomes (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting proposals for the R21 Exploratory/Developmental Research Grant under the funding opportunity titled "Innovations to Optimize HIV Prevention and Care Continuum Outcomes." This initiative aims to support innovative research that enhances HIV prevention and care strategies by exploring behavioral and social science approaches, new intervention methods, and implementation science, particularly addressing gaps in engagement, adherence, and retention in healthcare services. The grant, with a funding ceiling of $275,000 over two years, emphasizes collaboration with community organizations and the inclusion of diverse populations, aligning with national and global health objectives. Interested applicants can submit their proposals until January 9, 2026, and should direct inquiries to NIH Grants Information at grantsinfo@nih.gov.